Paolo Tarantino: The promise and challenges of response-adapted trials in breast oncology
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X about a recent paper by Jose Pérez-García, Medical Director of the International Breast Cancer Center, published in Nature Medicine:
“Recommended Nature Medicine read on the promise and challenges of response-adapted trials in breast oncology, with lessons from I-SPY and PHERGain neoadjuvant trials.”
“Moving toward response-adapted trials in oncology”
Authors: Jose Pérez-García, Gabriele Antonarelli, Maria Gion, Antonio Llombart-Cussac and Javier Cortés.
More posts featuring Paolo Tarantino.
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023